WOODLAND HILLS, California, USA, April 8, 2024 – Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the appointment of Michael H. Arenberg, J.D., M.B.A., as Chief Financial Officer (CFO), effective April 8^th, 2024.

Mike Arenberg has over 25 years of leadership experience in the biotechnology industry. Most recently, Mr. Arenberg served as Chief Operating Officer and Chief Business Officer of Imago BioSciences, where he was responsible for overseeing all capital market activities and led the deal process that resulted in a $1.35 billion acquisition by Merck in 2023. Prior to joining Imago, Mr. Arenberg was CFO and head of business development at Durect Corporation, a clinical-stage biopharmaceutical company, where he oversaw all financial and capital market activities. Over his career, Mr. Arenberg has served in a number of roles including head of finance, operations, strategy and business development and has negotiated over 70 strategic transactions to a successful close.

Mr. Arenberg earned his law degree from the University of Denver Sturm College of Law, and his M.B.A. from the Leavy School of Business at Santa Clara University.

David Ke, M.D., Chairman and Chief Executive Officer of Angitia, commented, “We are excited to welcome Mike as our CFO to the executive leadership team, as he brings deep experience in capital markets and business development, as well as strategic and operational expertise that complements our team.”

Mike Arenberg, incoming CFO of Angitia, also commented, “Angitia has developed an impressive pipeline, including multiple clinical candidates that each have the potential to become best-in-disease therapies. Angitia is poised for transformational growth in the coming years, and I look forward to joining David and the team to help advance these novel therapeutics to patients in need.”

About Angitia

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Leveraging the team's extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.

Learn more at www.angitiabio.com

Investor & Media Contact:

William Windham
Solebury Strategic Communications
wwindham@soleburystrat.com
646-378-2946

Forward-Looking Statement 

This press release is prepared by Angitia (the “Company", “We”) for informational purposes only. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “continue,” “could,” “potential,” “may,” “will,” “goal” or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words. 

These forward-looking statements are based on the current projects, expectations, assumptions, and understandings of the Company with respect to future events as of the date these statements are made. These statements are not a guarantee or warranty of future developments or otherwise.  

These statements involve substantial known and unknown risks, uncertainties, and other factors that are beyond the Company’s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. 

Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.